m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00501)
Target Name Ubiquitin carboxyl-terminal hydrolase 22 (USP22)
Synonyms
Deubiquitinating enzyme 22; Ubiquitin thioesterase 22; Ubiquitin-specific-processing protease 22
    Click to Show/Hide
Gene Name USP22
Chromosomal Location 17p11.2
Family Peptidase C19 family, UBP8 subfamily
Function
Histone deubiquitinating component of the transcription regulatory histone acetylation (HAT) complex SAGA. Catalyzes the deubiquitination of both histones H2A and H2B, thereby acting as a coactivator. Recruited to specific gene promoters by activators such as MYC, where it is required for transcription. Required for nuclear receptor-mediated transactivation and cell cycle progression.
    Click to Show/Hide
Gene ID 23326
Uniprot ID
UBP22_HUMAN
HGNC ID
HGNC:12621
Ensembl Gene ID
ENSG00000124422
KEGG ID
hsa:23326
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
USP22 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by ALKBH5
Cell Line 143B cell line Homo sapiens
Treatment: siALKBH5 transfected 143B cells
Control: siControl 143B cells
 GSE154528
Regulation
logFC: -2.53E+00
p-value: 1.55E-42
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary In osteosarcoma, ALKBH5 mediates its protumorigenic function by regulating m6A levels of histone deubiquitinase Ubiquitin carboxyl-terminal hydrolase 22 (USP22) and the ubiquitin ligase RNF40.
Target Regulation Up regulation
Responsed Disease Osteosarcoma ICD-11: 2B51
 Disease Info 
Pathway Response Ubiquitin mediated proteolysis hsa04120
Cell Process Proteasome pathway degradation
In-vitro Model U2OS Osteosarcoma Homo sapiens CVCL_0042
SaOS-2 Osteosarcoma Homo sapiens CVCL_0548
OS-17 Osteosarcoma Homo sapiens CVCL_9992
IMR-90 Normal Homo sapiens CVCL_0347
hFOB 1.19 Normal Homo sapiens CVCL_3708
143B Osteosarcoma Homo sapiens CVCL_2270
In-vivo Model For tumor xenograft studies, 143B cells stably expressing scrambled shRNA or ALKBH5 shRNA (1 × 106) were injected subcutaneously into the flanks of 4-week-old athymic nude mice.
Osteosarcoma [ICD-11: 2B51]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary In osteosarcoma, ALKBH5 mediates its protumorigenic function by regulating m6A levels of histone deubiquitinase Ubiquitin carboxyl-terminal hydrolase 22 (USP22) and the ubiquitin ligase RNF40.
Responsed Disease Osteosarcoma [ICD-11: 2B51]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Ubiquitin mediated proteolysis hsa04120
Cell Process Proteasome pathway degradation
In-vitro Model U2OS Osteosarcoma Homo sapiens CVCL_0042
SaOS-2 Osteosarcoma Homo sapiens CVCL_0548
OS-17 Osteosarcoma Homo sapiens CVCL_9992
IMR-90 Normal Homo sapiens CVCL_0347
hFOB 1.19 Normal Homo sapiens CVCL_3708
143B Osteosarcoma Homo sapiens CVCL_2270
In-vivo Model For tumor xenograft studies, 143B cells stably expressing scrambled shRNA or ALKBH5 shRNA (1 × 106) were injected subcutaneously into the flanks of 4-week-old athymic nude mice.
References
Ref 1 M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression. Cancer Res. 2022 May 16;82(10):1872-1889. doi: 10.1158/0008-5472.CAN-21-2106.